Home » Stocks » RDHL

RedHill Biopharma Ltd. (RDHL)

Stock Price: $8.59 USD -0.25 (-2.83%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $8.57 -0.02 (-0.23%) Dec 1, 6:30 PM

Stock Price Chart

Key Info

Market Cap 321.34M
Revenue (ttm) 6.29M
Net Income (ttm) -42.30M
Shares Out 37.41M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE 1,428.57
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $8.59
Previous Close $8.84
Change ($) -0.25
Change (%) -2.83%
Day's Open 9.06
Day's Range 8.38 - 9.10
Day's Volume 309,666
52-Week Range 3.51 - 10.83

More Stats

Market Cap 321.34M
Enterprise Value 277.28M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.41M
Float n/a
EPS (basic) -1.40
EPS (diluted) -1.80
FCF / Share -1.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.57M
Short Ratio 5.98
Short % of Float n/a
Beta 1.85
PE Ratio n/a
Forward PE 1,428.57
P/FCF Ratio n/a
PS Ratio 51.08
PB Ratio 11.61
Revenue 6.29M
Operating Income -43.20M
Net Income -42.30M
Free Cash Flow -40.92M
Net Cash 44.06M
Net Cash / Share 1.18
Gross Margin 9.06%
Operating Margin -686.71%
Profit Margin -672.50%
FCF Margin -650.41%
ROA -32.82%
ROE -246.27%
ROIC -221.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.20*
(146.80% upside)
Low
12.0
Current: $8.59
High
27.0
Target: 21.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6.298.364.010.10-7.010.010.020.02-
Revenue Growth-24.75%108.63%3867.33%3266.67%-99.96%58350%-25%-30.43%--
Gross Profit4.035.521.880.10-5.960.010.020.02-
Operating Income-43.20-39.33-51.13-30.54-21.90-10.65-10.77-9.04-7.87-1.25
Net Income-42.30-38.82-45.54-29.37-21.09-10.71-10.63-10.33-15.50-2.54
Shares Outstanding28421317112787.8864.4052.9952.99--
Earnings Per Share-1.40-1.70-2.60-2.40-1.90-1.30-1.70-2.00-3.20-2.70
Operating Cash Flow-40.75-34.46-44.77-28.26-17.83-12.23-8.44-6.80-4.69-1.63
Capital Expenditures-0.17-0.02-0.15-0.09-0.01-0.07-0.01-0.01-0.14-0.01
Free Cash Flow-40.92-34.49-44.92-28.34-17.84-12.30-8.45-6.80-4.83-1.64
Cash & Equivalents47.8753.1946.2166.1558.1422.9512.1118.3718.659.15
Total Debt3.82--------11.25
Net Cash / Debt44.0653.1946.2166.1558.1422.9512.1118.3718.65-2.09
Assets74.1062.4157.3474.2166.8328.8614.3420.1020.1910.51
Liabilities14.1011.2312.2811.516.753.852.421.081.4012.10
Book Value60.0051.1945.0762.7060.0825.0111.9319.0218.79-1.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name RedHill Biopharma Ltd.
Country Israel
Employees 155
CEO Dror Ben-Asher

Stock Information

Ticker Symbol RDHL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: RDHL

Description

RedHill Biopharma, a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.